JAMA/tukuz.com
Feb 7, 2026, 06:50
ACOG 2023 Guideline on Premenstrual Disorders – JAMA
JAMA shared a post on LinkedIn:
“JAMA Clinical Guidelines Synopsis: The 2023 American College of Obstetricians and Gynecologists guideline on the management of premenstrual disorders recommends selective serotonin reuptake inhibitors (SSRIs)—used intermittently or continuously—as effective for affective symptoms, with evidence supporting their use.
Combined oral contraceptive pills, particularly those containing drospirenone, and cognitive behavior therapy are also recommended.
Treatment selection should consider individual patient goals, presence of affective or physical symptoms, and need for contraception.”
Stay updated on all scientific advances in the field of fertility with Fertility News.
-
Apr 3, 2026, 12:57Sergei Gorlovetsky: The Invisible Work Breaking Fertility Clinics
-
Apr 3, 2026, 12:50Ting Yuan: Rethinking Oocyte Quality Through Reproducible Patterns
-
Apr 3, 2026, 12:36Asma Khalil: An Incredibly Powerful Podcast Brings Attention to Women’s Fertility Challenges
-
Apr 3, 2026, 12:29Angela Koech: Every 30 Seconds, Africa Loses a Baby to a Preventable Stillbirth
-
Apr 3, 2026, 12:17Sergei Gorlovetsky: AI Support Expands Guidance for IVF Patients at Home
-
Apr 3, 2026, 12:06Thin Womb Lining Doesn’t Have to End Your IVF Dreams – Fertility Plus
-
Apr 3, 2026, 12:04Updated NICE IVF Guidance Contrasts with Declining NHS Support – HFEA
-
Apr 3, 2026, 11:59IVF Remains Safe for Women With a History of Cancer – ESHRE
-
Apr 3, 2026, 11:56Vitamin D Binding Protein and Reproductive Outcomes – Fertility and Sterility